retatrutide type 2 diabetes phase 2 weight loss 2024 Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in and A1C ADA26: retatrutide delivers unprecedented weight

We believe this holistic approach maximizes your treatment success and helps you maintain lasting results

Choose a formula that delivers multiple skin benefits

Important context for 2026: GLP-1 telehealth programs and compounded semaglutide and tirzepatide have been subject to evolving regulatory scrutiny

10.1016/j.jnutbio.2025.109952 Summary Keywords phenolic acids, fermentation, health benefits, microbial biotransformation, antioxidants, functional foods Citation Kumar A, Saranyadevi S, Thirumalaisamy SK, Dapana Durage TT, Jaiswal SG, Kavitake D and Wei S (2025) Phenolic acids in fermented foods: microbial biotransformation, antioxidant mechanisms, and functional health implications

News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist